Shares of Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) were up 7.4% during mid-day trading on Monday. The stock traded as high as $29.79 and last traded at $29.7880. Approximately 555,460 shares were traded during trading, an increase of 26% from the average session volume of 439,233 shares. The stock had previously closed at $27.74.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on PHVS. Citigroup reiterated a “market outperform” rating on shares of Pharvaris in a research note on Wednesday, September 9th. Morgan Stanley raised their price target on shares of Pharvaris from $46.00 to $62.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 9th. Leerink Partners lifted their price target on shares of Pharvaris from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 9th. Guggenheim lifted their price target on shares of Pharvaris from $40.00 to $44.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $75.00 price target on shares of Pharvaris in a report on Tuesday, September 8th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Pharvaris presently has an average rating of “Moderate Buy” and an average target price of $58.60.
Check Out Our Latest Analysis on PHVS
Pharvaris Price Performance
The firm’s 50-day moving average price is $34.41 and its 200 day moving average price is $32.47. The firm has a market cap of $1.95 billion, a P/E ratio of -9.74 and a beta of -2.46.
Pharvaris (NASDAQ:PHVS – Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Analysts forecast that Pharvaris N.V. will post -3.12 earnings per share for the current year.
Insider Activity at Pharvaris
In other Pharvaris news, President Peng Lu sold 100,000 shares of the stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $35.00, for a total transaction of $3,500,000.00. Following the transaction, the president owned 64,953 shares of the company’s stock, valued at $2,273,355. This trade represents a 60.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Elisabeth Bjork sold 52,500 shares of Pharvaris stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $37.89, for a total value of $1,989,225.00. Following the completion of the transaction, the director owned 15,167 shares of the company’s stock, valued at approximately $574,677.63. The trade was a 77.59% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 513,102 shares of company stock worth $18,643,666 over the last quarter.
Hedge Funds Weigh In On Pharvaris
Several large investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new position in Pharvaris in the second quarter worth $41,000. CoreCap Advisors LLC bought a new stake in Pharvaris during the second quarter valued at $93,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Pharvaris during the second quarter worth $196,000. Algert Global LLC acquired a new stake in shares of Pharvaris during the second quarter worth $238,000. Finally, Persistent Asset Partners Ltd bought a new position in shares of Pharvaris in the 2nd quarter worth about $273,000.
About Pharvaris
Pharvaris N.V. (NASDAQ:PHVS) is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE) and other diseases associated with bradykinin-mediated swelling. HAE is a rare genetic disorder that can cause recurring, potentially life-threatening attacks affecting areas such as the skin, gastrointestinal tract and airways.
The company’s lead program is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist formerly known as PHA121.
See Also
- Five stocks we like better than Pharvaris
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
